Cardiac Insight partners with VivoSense to expand use of its wearable cardiac sensors

373
Cardiac Insight
Cardea SOLO

Cardiac Insight, Inc., a developer of wearable cardiac biosensors and clinical diagnostic software systems featuring proprietary automated data analysis algorithms, has announced its partnership with VivoSense, a company focused on integration and specialised analysis of wearable sensor data for research and clinical trials. Together, both companies hope to deliver enhanced research analytics to help VivoSense expand the use of wearable biosensors for pharmaceutical clinical trials and other healthcare applications.

“Sophisticated new analytics are the key to making sense of the complex data sets generated by human study participants in response to new drug candidates and genetics-driven population health research. Using the class-leading Cardiac Insight Cardea SOLO ECG Sensor data with VivoSense software, data cleaning, robust analytics and regulatory-compliant biomarkers, we expect to enable new discoveries,” said Dudley Tabakin, chief executive officer and co-founder of VivoSense. “The unique attributes and access to data enabled by Cardea SOLO strongly support our mission to advance clinical trials through the increasing use of wearable technology.”

VivoSense ingests data from many different wearable sensors, from high-resolution cardiorespiratory and other cardiac sensors to wrist-worn activity trackers. This data from on-body sensors is integrated, cleaned and synchronously analysed with robust algorithms and scientific oversight from the VivoSense platform. The technology opens all clinical trials to the accurate use of wearable technology, providing a new level of data.

“Our partnership with VivoSense is forging new frontiers and capabilities in healthcare research. Our complex raw ECG data and automated analytics, easily obtained by our wearable ECG, Cardea SOLO, combined with the VivoSense platform integration will provide a new level of understanding into the effectiveness of emerging medical and pharmaceutical innovations, as well as to potentially develop completely new biomarkers,” said Brad Harlow, chief executive officer of Cardiac Insight. “Contributing to the advancement of health research is an important component of our mission. We look forward to providing researchers a more comprehensive level of data analytics to improve disease prevention, detection and treatment.”

Comfortable and unobtrusive wearable cardiorespiratory sensors are finding ubiquitous use in sports and fitness research, longitudinal healthcare monitoring, and in regulated clinical trials. The very large physiological data sets generated by these sensors are the key to monitoring health and providing a greater understanding of the effects of new medicines and therapies.

(Visited 128 times, 2 visits today)

LEAVE A REPLY

Please enter your comment!
Please enter your name here